ADX-850 / ADARx - LARVOL DELTA

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: ADARx Pharmaceuticals, Inc. | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial primary completion date • Cardiovascular • Hypertension

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: ADARx Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting | N=120 ➔ 28

Enrollment change • Enrollment closed • Cardiovascular • Hypertension

Safety, Tolerability, PK and PD of ADX-850 in Participants with Hypertension (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: ADARx Pharmaceuticals, Inc. | N=72 ➔ 120 | Trial completion date: Jun 2026 ➔ Sep 2026

Enrollment change • Trial completion date • Cardiovascular • Hypertension

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: ADARx Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

Safety, Tolerability, PK and PD of ADX-850 in Patients With Hypertension (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: ADARx Pharmaceuticals, Inc.

New P1 trial • Cardiovascular • Hypertension